Overview

First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid Arthritis

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability, pharmacokinetic (the effect of the body on the investigated drug) and signs of clinical efficacy of increasing single doses or four repeated doses of NNC 0142-0002 in patients with rheumatoid arthritis.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC